CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Arch Biopartners Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Arch Biopartners Inc
545 King St W.
Phone: (647) 428-7031p:647 428-7031 TORONTO, ON  M5X 1A1  Canada Ticker: ACHACH
Business Summary
Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury (AKI) and organ damage caused by inflammation and toxins. The Company is developing a platform of novel drugs targeting the dipeptidase-1 (DPEP1) inflammation pathway prevalent in the kidneys, lungs and liver. The Company is advancing a pipeline of drug candidates that includes LSALT peptide, a first-in-class inhibitor of the DPEP1 inflammation pathway, and cilastatin, a repurposed drug with off-target effects that help block toxin uptake into the kidneys - two approaches addressing distinct and urgent causes of AKI. The Company is ongoing Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). Cilastatin is particularly suited to preventing AKI caused by exogenous and endogenous toxins due to an off-target effect that blocks their uptake into the kidney tissue.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20259/30/2024Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director RichardMuruve 1/1/2021 8/11/2005
Chief Financial Officer, Director AndrewBishop 1/1/2022 4/1/2010
Chief Science Officer DanielMuruve 1/1/2013 1/1/2013
Independent Director ClaudeAllary 12/1/2014 4/17/2014
Independent Director RichardRossman 1/1/2020 5/1/2010

Business Names
Business Name
1495628 AB ltd
1502440 AB Ltd
ACH
9 additional Business Names available in full report.

General Information
Number of Employees: 10 (As of 12/31/2002)
Outstanding Shares: 65,906,366 (As of 4/4/2025)
Shareholders: 600
Stock Exchange: CVE
Fax Number: (647) 351-3565


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, June 5, 2025